XML 26 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 09, 2022
Jun. 30, 2021
Cover [Abstract]      
Entity Registrant Name ACORDA THERAPEUTICS, INC.    
Entity Central Index Key 0001008848    
Document Type 10-K    
Document Period End Date Dec. 31, 2021    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Public Float     $ 52,234,372
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Document Annual Report true    
Document Transition Report false    
Entity Common Stock, Shares Outstanding   13,250,296  
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity File Number 001-31938    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 13-3831168    
Entity Address, Address Line One 420 Saw Mill River Road    
Entity Address, City or Town Ardsley    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10502    
City Area Code 914    
Local Phone Number 347-4300    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Stamford, Connecticut    
Title of each class Common Stock $0.001 par value per share    
Trading Symbol ACOR    
Name of each exchange on which registered NASDAQ    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

The registrant intends to file a proxy statement for its 2022 Annual Meeting of Stockholders pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2021. Portions of the proxy statement are incorporated herein by reference into the following parts of the Form 10-K:

Part III, Item 10, Directors, Executive Officers and Corporate Governance.

Part III, Item 11, Executive Compensation.

Part III, Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Part III, Item 13, Certain Relationships and Related Transactions, and Director Independence.

Part III, Item 14, Principal Accounting Fees and Services.